A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors.
Gulam A ManjiBrian Andrew Van TineShing M LeeAlexander G RaufiIlenia PellicciottaAngela C HirbeJaya PradhanAndrew X ChenRaul RabadanGary K SchwartzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Pexidartinib can be safely administered with sirolimus. These findings support further investigation of this combination to determine clinical efficacy. Clinicaltrials.gov identifier NCT02584647.